|

Induction chemoimmunotherapy Clinical Trials

2 actively recruiting trials

▲ +1 trial since July 2026

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Sun Yat-sen University1
  • Shanghai Chest Hospital1

Indications

  • Cancer2
  • Unresectable Stage III NSCLC1
  • Locally Advanced Non-Small Cell Lung Cancer1
  • Esophageal Squamous Cell Carcinoma (ESCC)1
  • Lung Cancer1

Other2 trials

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Phase 2
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.